Navigation Links
Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
Date:1/31/2008

XI'AN, China, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ("Skystar", "Company"), a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that the Company is raising its guidance for 2007 revenue to $15.8 million. The Company previously announced 2007 revenue guidance to be in the range of $12 - $14 million.

"We are proud to announce the first year operating our new veterinary medicine facility we exceeded our revenue target for 2007. Our success in achieving our record revenue is the result of expanding our product line with 62 new drug approvals, increasing our market penetration and implementing an aggressive marketing campaign," commented Skystar's Chief Executive Officer, Mr. Weibing Lu. "We look forward to another strong year for 2008 as our new vaccine facility is expected to begin large-scale production in the second half of the year."

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company's product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The Company recently completed construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of management and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Such factors include, but are not limited to the Company's ability to develop new products, market acceptance of the company's new products, ability to obtain the regulatory approvals or clearances that are necessary to commercialize its products, ability to protect proprietary rights, political and economic factors in the People's Republic of China and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Scott Cramer

Director - U.S. Representative

Skystar Bio-Pharmaceutical Co., Ltd.

Tel: +1-407-645-4433

Email: scramer@skystarbio-pharmaceutical.com

Crocker Coulson, President

CCG Elite Investor Relations

Email: crocker.coulson@ccgir.com

Leslie Richardson, Financial Writer

CCG Elite Investor Relations

Tel: 310-231-8600 x 122

Email: leslie.richardson@ccgir.com


'/>"/>
SOURCE Skystar Bio-Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
2. Pearl Therapeutics Raises $15.5 Million in Private Financing
3. Enobia Pharma Raises $40.1 Million Series B Financing
4. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. VisEn Medical Raises $7 Million in Series B Financing
7. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
9. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
10. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... February 16, 2017 Patient ... of innovative telemedicine application, new and leading edge ... experiencing a boom worldwide. The healthcare sector as ... technologies, services and new therapies for companies such ... RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure ... was performed on a 55-year-old practicing female physician suffering from degenerative disc disease ...
(Date:2/16/2017)... , ... February 16, 2017 ... ... Molecular Research Inc. has further extended its industry leading Biochemistry Services specifically ... offers state-of-the-art cGMP techniques and methods for the biochemical and biosimilar ...
Breaking Biology Technology:
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):